Humanized CART19 Phase 2 Trial

This purpose of this study isto determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and youngadult patients with high-risk relapsed or refractory B-cell acute lymphoblasticleukemia (B-ALL). You may be eligible to participate if you are between theages of 1-29 years with CD19-expressing B-ALL that is refractory tochemotherapy, has relapsed in the bone marrow <36 months from diagnosis,relapsed more than once, or relapsed after bone marrow transplant or afterprevious CAR T cell therapy. This study involves the administration of thestudy drug, blood draws, assessment of leukemia response, chart reviews, andquestionnaires. Reimbursement for travel may be provided. If you have questionsor would like to learn more about the study, please contact the CancerImmunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. ShannonMaude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.